A qualitative shift in the treatment of obesity: a new oral medicine and without nutritional conditions

The results of a recent study showed that a new remedy called Orforglberbron) was taken orally once a day to significantly lose weight, which is not infected with type 2 diabetes. The study, which was presented at the activities of the EUROPEAN Society for Diabetes Study, held in the city of Vienna in Austria between 15 and 19 September, is one of the most prominent research in the field of obesity, during the current year, because it provides for the first time wide data on oral treatment of the GLP-1, which is the same pharmaceutical category, which is the same pharmaceutical category. Like a pharmaceutical revolutionation of the treatment of old, through infection medicine, such as a pharmaceutical way is to make a revolution “and the treatment of guys from parents, such a pharmaceutical remedy” lyraglaid “. This medicine works by stimulating a special future in the body called the future of peptide-like peptide-1, when the future stimulates, increases insulin secretion when blood sugar rises, and the secretion of glucagon, which is the hormone that slows down the level of the feeling of food and reduces the amount of food, and also the appetites affect the desire in the desire. And “Orforperbrones” is a small and non-protein medicinal compound, which works as a catalyst for the future of the Bruceh-1-Peptide-1, and it was developed by the company “Eli Lily” after its first discovery in the Japanese company “choujay” and then the license in 2018. The results of the study, published by the New England Journal of Medicine, showed that the drug led to a weight reduction dependent on the size of the dose; The average decrease reached 7.5% at a dose of 6 ml, and 8.4% at a dose of 12 ml, reaching 11.2% at a dose of 36 milliliters, compared to a limited decrease that was no more than 2.1% in the imaginary drug group. In the group, which received a dose of 36 ml, the weight of more than half of the participants fell (54.6%) at a rate of 10%, while the weight of 36% fell by at least 15%, while 18.4% of participants lost 20% or more of the weight. Participants who consumed ‘Orforperbron’ recorded an improvement in the perimeter of the waist and systolic blood pressure, in addition to a decrease in triglycerides and non -high -density cholesterol, and inflammatory indicators, including high -allergic reactor protein. The most common side effects were related to the digestive system, such as nausea and diarrhea, most of which were light to average intensity, and side effects led to a stop between 5.3 and 10.3% of patients from the treatment, compared to only 2.7% in the control group. Previous research has concluded that the injected GLP-1 medicine such as “Simajlotide” can lead to a reduction of the weight of between 15 and 20% and more, but the new oral form can give an advantage associated with the ease and increased access, especially in countries or groups facing challenges used by injection. The first author of the study, Sean Warton, a researcher at McMaster University in Canada. He added: “The results of this study may enable the extent of the treatment to include categories that could not benefit from the previous medicine due to the cost or trouble to follow the injection.” Some of the most important strengths in the study are the large sample size and geographical diversity as it includes 9 countries of four continents, while restrictions are in the absence of a direct comparison with other approved medicines to treat obesity, and the use of body mass index standards based on data associated with the white population, which can reduce the comprehensiveness of other population groups. So far, Urforcelbron has not obtained the approval of the US Food and Drug Administration or any other organizational body, but the current results are an important step to adopt it as a new option to treat obesity.